Clearside Biomedical Inc - Asset Resilience Ratio
Clearside Biomedical Inc (CLSD) has an Asset Resilience Ratio of 33.27% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Clearside Biomedical Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2019)
This chart shows how Clearside Biomedical Inc's Asset Resilience Ratio has changed over time. See CLSD equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Clearside Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CLSD company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.70 Million | 33.27% |
| Total Liquid Assets | $9.70 Million | 33.27% |
Asset Resilience Insights
- Very High Liquidity: Clearside Biomedical Inc maintains exceptional liquid asset reserves at 33.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Clearside Biomedical Inc Industry Peers by Asset Resilience Ratio
Compare Clearside Biomedical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Clearside Biomedical Inc (2016–2019)
The table below shows the annual Asset Resilience Ratio data for Clearside Biomedical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $26.78 Million | -- |
| 2018-12-31 | 74.42% | $32.84 Million | $44.12 Million | +4.25pp |
| 2017-12-31 | 70.18% | $28.42 Million | $40.49 Million | +12.63pp |
| 2016-12-31 | 57.55% | $48.81 Million | $84.81 Million | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more